Asthma/COPD Stepwise Therapy - Pharmacology

1. A patient with severe eosinophilic asthma is maintained on high-dose ICS/LABA and tiotropium. To gain control, they require frequent courses of oral prednisone and are considered oral corticosteroid-dependent. Addition of which agent is most likely to have a significant oral corticosteroid-sparing effect in this patient?
   Answer: Benralizumab Benralizumab is a biologic agent that targets the IL-5 receptor alpha on eosinophils, leading to their depletion. In patients with severe, uncontrolled eosinophilic asthma, anti-IL-5 pathway biologics (like benralizumab, mepolizumab, reslizumab) have been shown to significantly reduce exacerbations and decrease the required daily dose of oral corticosteroids. Theophylline and cromolyn are older, less effective agents. Roflumilast is indicated for COPD, not asthma.
2. A 70-year-old patient with severe COPD (GOLD Group D) is treated with a fluticasone/vilanterol (ICS/LABA) inhaler. They continue to have one to two moderate exacerbations per year. Their blood eosinophil count is 220 cells/μL. What is the most appropriate next step to optimize their regimen?
   Answer: Add a long-acting muscarinic antagonist (LAMA). This patient is on dual therapy (ICS/LABA) but continues to have exacerbations. The next logical step in the GOLD algorithm is to escalate to triple therapy by adding a LAMA. This creates an ICS/LABA/LAMA regimen, which has been shown to be superior to dual therapy for reducing exacerbations in appropriate patients. Discontinuing the ICS would be inappropriate given the eosinophil count (>100) and exacerbation history. Increasing the ICS/LABA dose is less effective than adding a new drug class. Azithromycin is an option for former smokers but adding a LAMA is the primary pharmacologic step-up.
3. A 22-year-old with moderate persistent asthma admits to being frequently non-adherent with their daily controller inhaler. To simplify the regimen and improve adherence, their physician suggests a strategy using a single inhaler for both maintenance and reliever therapy (MART/SMART). Which medication combination is suitable for this strategy?
   Answer: Budesonide/formoterol The MART (Maintenance and Reliever Therapy) or SMART (Single Maintenance and Reliever Therapy) strategy requires an ICS combined with a LABA that has a fast onset of action. Formoterol has a rapid onset (within 1-3 minutes), similar to albuterol, making budesonide/formoterol suitable for this purpose. Salmeterol (in fluticasone/salmeterol) has a slower onset and is not approved for use as a reliever. Ipratropium/albuterol is a SAMA/SABA combination used for COPD, and tiotropium/olodaterol is a LAMA/LABA for COPD maintenance.
4. A 29-year-old woman who is 18 weeks pregnant has worsening asthma symptoms, requiring her SABA 3-4 times per week. She is not currently on any controller medication. Which of the following is the most appropriate controller medication to initiate, based on extensive safety data in pregnancy?
   Answer: Inhaled budesonide When treating asthma in pregnancy, you need to balance effective symptom control with fetal safety. This patient's symptoms (requiring SABA 3-4 times weekly) indicate inadequate control that warrants controller therapy, as uncontrolled asthma poses greater risks to both mother and fetus than appropriately chosen medications. Inhaled budesonide (D) is the most appropriate choice because it has the most extensive safety data in pregnancy among inhaled corticosteroids. Multiple large studies and registries have demonstrated no increased risk of birth defects or adverse pregnancy outcomes. The FDA classifies it as pregnancy category B, and major guidelines specifically recommend budesonide as the preferred inhaled corticosteroid during pregnancy. Montelukast (A) has limited pregnancy safety data compared to budesonide. While it's pregnancy category B, the evidence base is much smaller, making it a second-line option when inhaled corticosteroids are contraindicated or ineffective. Oral theophylline (B) has a narrow therapeutic window requiring frequent monitoring, and serum levels can be unpredictably altered by pregnancy-related physiological changes. It also carries risks of maternal and fetal toxicity. The fluticasone/salmeterol combination (C) contains fluticasone, which has less pregnancy safety data than budesonide. Additionally, starting with a combination therapy bypasses the stepwise approach recommended in pregnancy management. Remember this principle: for asthma in pregnancy, budesonide is the gold-standard inhaled corticosteroid due to its extensive safety profile. When you see pregnancy + asthma controller therapy, think budesonide first.
5. A patient with moderate persistent asthma is well-controlled on a daily maintenance inhaler of fluticasone propionate/salmeterol. What is the appropriate medication to be prescribed for as-needed quick relief of symptoms?
   Answer: An as-needed short-acting beta-agonist (SABA) inhaler. When a patient's maintenance therapy is a non-formoterol-containing ICS/LABA combination (like fluticasone/salmeterol), the designated reliever medication is a SABA (e.g., albuterol). Salmeterol has a slow onset of action and is not suitable for quick relief. Using an ICS/formoterol inhaler as a reliever is only appropriate when it is also the maintenance inhaler (MART/SMART therapy). Ipratropium, a SAMA, is not the first-line reliever for asthma.
6. A 34-year-old patient with asthma has been well-controlled on a medium-dose fluticasone/salmeterol inhaler (ICS/LABA) for the past 6 months, with no exacerbations and minimal SABA use. A decision is made to attempt a step-down in therapy. Which of the following is the most appropriate initial step-down strategy?
   Answer: Reduce the regimen to a low-dose fluticasone/salmeterol combination inhaler. When a patient's asthma is well-controlled for at least 3 months, a step-down in therapy can be considered to find the lowest effective dose. The preferred initial step-down from a medium-dose ICS/LABA is to reduce it to a low-dose ICS/LABA. Stopping the LABA completely is another option but reducing the ICS dose first while maintaining dual therapy is often preferred. Stopping all controller therapy is inappropriate for a patient who required a medium-dose ICS/LABA for control. Discontinuing the ICS while continuing the LABA is contraindicated in asthma due to increased risk of severe exacerbations.
7. A 65-year-old patient with GOLD Group B COPD is being treated with tiotropium (a LAMA). At a 3-month follow-up visit, they have had no exacerbations but continue to complain of significant dyspnea (mMRC score of 2). According to the GOLD follow-up algorithm, what is the most appropriate adjustment to their therapy?
   Answer: Add a long-acting beta-agonist (LABA). The patient's predominant treatable trait is dyspnea, not exacerbations. The GOLD follow-up algorithm for persistent dyspnea on monotherapy recommends escalating to dual bronchodilator therapy. Therefore, adding a LABA to the existing LAMA is the correct step. Adding an ICS or roflumilast is recommended for the exacerbation pathway, not for managing persistent dyspnea alone. Switching from a LAMA to a LABA would be a lateral move and is less effective than using both together.
8. A 67-year-old male with severe COPD (FEV1 35% predicted) and chronic bronchitis is on triple therapy (ICS/LAMA/LABA). He continues to have frequent exacerbations despite optimal inhaler technique. His blood eosinophil count is 90 cells/μL. What is the most appropriate next therapeutic addition?
   Answer: Roflumilast When treating severe COPD patients with frequent exacerbations despite optimal triple therapy, you need to consider add-on therapies based on specific patient characteristics and phenotypes. This patient has severe COPD with chronic bronchitis phenotype and continues exacerbating despite ICS/LAMA/LABA therapy. The key detail is his low eosinophil count (90 cells/μL), which helps guide treatment selection. Roflumilast (D) is the correct choice because it's a phosphodiesterase-4 (PDE4) inhibitor specifically indicated for severe COPD patients with chronic bronchitis phenotype and frequent exacerbations. It reduces inflammation by increasing cyclic adenosine monophosphate (cAMP) levels and is particularly effective in patients with lower eosinophil counts. Omalizumab (A) is an anti-IgE monoclonal antibody used primarily for allergic asthma, not COPD. It's inappropriate here since this patient has COPD without evidence of allergic disease. Increasing ICS dose (B) is unlikely to provide additional benefit and may increase side effects, especially since he already has low eosinophils (suggesting less steroid-responsive inflammation). Long-term oral prednisone (C) is generally avoided in COPD due to significant systemic side effects including osteoporosis, diabetes, and increased infection risk, with minimal proven benefit for stable disease. Remember that COPD add-on therapy selection depends on phenotype identification: roflumilast works best for chronic bronchitis with frequent exacerbations, while newer biologics target specific inflammatory pathways. Always consider eosinophil count as it helps predict steroid responsiveness and guides personalized treatment decisions.
9. A 75-year-old man is newly diagnosed with GOLD Group B COPD. His medical history is significant for severe benign prostatic hyperplasia (BPH) with urinary retention and glaucoma. Which initial monotherapy would be the most prudent choice?
   Answer: Indacaterol (LABA) Both tiotropium and aclidinium are LAMAs, which act as anticholinergics. Anticholinergic agents can worsen urinary retention in patients with BPH and can precipitate acute angle-closure glaucoma. Therefore, a LABA such as indacaterol would be a safer initial choice for bronchodilation in this patient. ICS monotherapy is not recommended for COPD.
10. A 68-year-old male with a significant smoking history is newly diagnosed with COPD. His FEV1 is 48% of predicted. He reports an mMRC dyspnea scale score of 3 and has been hospitalized once for an acute exacerbation in the past year. His blood eosinophil count is 150 cells/μL. Based on the GOLD 2023 guidelines, what is the most appropriate initial pharmacologic therapy?
    Answer: A long-acting muscarinic antagonist (LAMA) and long-acting beta-agonist (LABA) combination. The patient's high symptom burden (mMRC > 2) and history of a severe exacerbation (hospitalization) place him in GOLD Group D. The recommended initial therapy for Group D is a LAMA/LABA combination. LAMA monotherapy is for Group C. An ICS/LABA could be considered if eosinophils were >300 cells/μL, but at 150, dual bronchodilation is the preferred starting point. SABA as needed is only appropriate for low-risk, low-symptom Group A patients.
11. A 45-year-old patient with persistent asthma is currently managed with a low-dose inhaled corticosteroid (ICS). They report using their albuterol inhaler 4-5 times per week for symptom relief and have been awakened by coughing twice in the past month. Their FEV1 is 75% of predicted. According to GINA guidelines, what is the most appropriate next step in management?
    Answer: Add a long-acting beta-agonist (LABA) to the current low-dose ICS. The patient's symptoms indicate that their asthma is not well-controlled on low-dose ICS monotherapy (Step 2). The preferred next step (Step 3) in the GINA guidelines for adults is to add a LABA to the low-dose ICS. While increasing the ICS to a medium dose is an alternative, adding a LABA is generally preferred and often more effective for improving lung function and reducing symptoms. Adding a LAMA is typically reserved for Step 4 or 5. Adding montelukast is an alternative but is generally less effective than adding a LABA.
12. A patient with stable COPD on LAMA/LABA therapy reports a persistently high CAT score of 22, primarily due to dyspnea. They have not had an exacerbation in over a year. Pharmacologic therapy has been optimized. Which intervention should be prioritized as the next step in their management plan?
    Answer: Enrollment in a comprehensive pulmonary rehabilitation program. When a COPD patient on optimal dual bronchodilator therapy still has persistent dyspnea (the 'dyspnea pathway' in GOLD), non-pharmacologic interventions are crucial. Pulmonary rehabilitation is a cornerstone of COPD management that has been proven to improve dyspnea, exercise capacity, and quality of life. Adding an ICS or roflumilast is indicated for patients with an exacerbation-predominant phenotype. Switching inhaler devices without a clear reason is unlikely to provide significant benefit.
13. A 72-year-old patient with COPD has been on triple therapy (ICS/LABA/LAMA) for three years. He has been exacerbation-free for the past year but has developed pneumonia twice in that period. His most recent blood eosinophil count is 80 cells/μL. What is the most appropriate therapeutic adjustment?
    Answer: Discontinue the inhaled corticosteroid (ICS) component. GOLD guidelines recommend considering ICS withdrawal in patients with a history of pneumonia, a low likelihood of ICS benefit (eosinophils < 100 cells/μL), and who are stable without exacerbations. This patient meets all criteria. Discontinuing the ICS and continuing with dual LAMA/LABA bronchodilation is the most appropriate step to reduce the risk of future pneumonia without compromising control. Bronchodilators (LAMA, LABA) are the foundation of COPD therapy and should not be discontinued.
14. A 14-year-old is diagnosed with asthma. Symptoms occur less than twice per month, and he had one nighttime awakening due to his asthma in the past month. He has no risk factors for exacerbations. According to GINA guidelines, which treatment plan would represent overtreatment for this patient's initial presentation?
    Answer: Prescribing a daily low-dose inhaled corticosteroid and an as-needed SABA. When you encounter asthma management questions, always start by classifying the severity using GINA guidelines. This patient presents with symptoms less than twice monthly and only one nighttime awakening in the past month, which clearly indicates intermittent asthma - the mildest classification. The correct answer is D because prescribing daily inhaled corticosteroids (ICS) plus as-needed SABA represents treatment for mild persistent asthma, not intermittent asthma. GINA guidelines reserve daily controller therapy for patients with symptoms more than twice weekly or frequent nighttime awakenings. Using daily ICS in intermittent asthma constitutes overtreatment and exposes the patient to unnecessary medication burden and potential side effects. Let's examine why the other options are appropriate: A is actually GINA's preferred first-line treatment - as-needed low-dose ICS/formoterol provides both immediate bronchodilation and anti-inflammatory effects while avoiding daily medication. B represents essential non-pharmacological management that's appropriate for all asthma patients regardless of severity. C describes the traditional as-needed SABA approach, which while not preferred due to lack of anti-inflammatory action, isn't considered overtreatment for intermittent asthma. Study tip: Remember the GINA stepped approach - match treatment intensity to disease severity. Intermittent asthma needs intermittent treatment, not daily controllers. When you see very infrequent symptoms (less than twice monthly), think "as-needed" therapy only. Daily medications are reserved for persistent asthma with more frequent symptoms.
15. A patient with severe COPD is maintained on dual bronchodilator therapy (LAMA/LABA). Despite this, they have experienced two moderate exacerbations in the past year. The physician is considering adding an inhaled corticosteroid (ICS). The addition of an ICS is most strongly supported by which of the following laboratory findings?
    Answer: Blood eosinophil count > 300 cells/μL According to GOLD guidelines, the strongest predictor of a positive response to inhaled corticosteroids for exacerbation reduction in COPD is a peripheral blood eosinophil count > 300 cells/μL. While a low FEV1 was historically used, eosinophil count is now the preferred biomarker. Elevated IgE is relevant for allergic asthma, not typically for guiding ICS therapy in COPD. A history of pneumonia is a relative contraindication to ICS therapy, as it can increase pneumonia risk.
16. A 40-year-old patient's asthma is inadequately controlled on a medium-dose ICS/LABA combination. They use their reliever inhaler most days of the week and have an FEV1 of 68% predicted. According to GINA guidelines, which intervention is a recommended next step (Step 4 to Step 5)?
    Answer: Refer for phenotypic assessment and consideration of add-on therapy like a LAMA. The patient is at GINA Step 4 and is not controlled. The next step is to move to Step 5, which involves referral to a specialist for phenotypic assessment. Add-on therapies at this stage include a LAMA (e.g., tiotropium), or biologic agents if specific criteria are met. While increasing to high-dose ICS/LABA is also a Step 4/5 option, referral and considering a new class like a LAMA is a key part of this step-up. Montelukast is a less effective add-on at this stage. Oral corticosteroids are for acute exacerbations, not chronic step-up. Switching to high-dose ICS monotherapy would be a step-down in bronchodilation and is inappropriate.
17. A 62-year-old lifelong non-smoker with a history of adult-onset allergies presents with wheezing and dyspnea. Spirometry shows an FEV1/FVC ratio of 0.68, which improves by 18% and 250 mL after albuterol administration. Blood eosinophils are 400 cells/μL. This presentation is suggestive of Asthma-COPD Overlap (ACO). Which initial controller therapy would be most appropriate?
    Answer: Low-dose fluticasone/salmeterol (ICS/LABA). This patient has features of both asthma (non-smoker, allergies, significant bronchodilator reversibility, high eosinophils) and COPD (persistent airflow limitation). In cases of diagnostic uncertainty or ACO, treatment should always include an inhaled corticosteroid (ICS) due to the risks associated with untreated asthma. Therefore, an ICS/LABA combination is the most appropriate initial therapy. LAMA or LABA monotherapy would fail to treat the underlying inflammation and would be dangerous if the predominant process is asthma. Roflumilast is for specific COPD phenotypes.
18. A 58-year-old with a 30-pack-year smoking history presents with cough and dyspnea. After a thorough workup including spirometry, a definitive diagnosis of asthma is made. Which of the following initial controller monotherapy regimens would be contraindicated?
    Answer: Salmeterol In patients with asthma, long-acting beta-agonist (LABA) monotherapy, such as with salmeterol, is contraindicated. It has been associated with an increased risk of asthma-related death when not used in combination with an inhaled corticosteroid (ICS). Although LABA monotherapy is an acceptable treatment for COPD, the patient's definitive diagnosis is asthma, making this choice incorrect and dangerous. Low-dose ICS (budesonide, fluticasone) is the cornerstone of asthma controller therapy, and montelukast is an alternative.
19. A patient with severe asthma remains uncontrolled despite high-dose ICS/LABA combination therapy and an added LAMA (tiotropium). They have had three exacerbations requiring oral steroids in the past year. Laboratory workup reveals a blood eosinophil count of 500 cells/μL and normal serum IgE levels. What is the most appropriate biologic agent to add to their regimen?
    Answer: Mepolizumab This patient has severe eosinophilic asthma, as evidenced by the high eosinophil count (>150-300 cells/μL) and persistent exacerbations despite maximal standard therapy. Mepolizumab is an anti-IL-5 antibody that specifically targets the eosinophilic pathway and is indicated for this phenotype. Omalizumab is an anti-IgE antibody for allergic asthma, which is less likely given the normal IgE. Dupilumab (anti-IL-4/13) and Tezepelumab (anti-TSLP) are also options for severe asthma, but Mepolizumab is a classic, direct choice for a purely eosinophilic picture. In this context, it's the most targeted therapy presented.
20. A 20-year-old is diagnosed with mild persistent asthma, with symptoms occurring about 3 times per week. According to the GINA guidelines' preferred approach (Track 1) for initial therapy at Step 2, which regimen is recommended?
    Answer: As-needed low-dose ICS/formoterol combination. The GINA guidelines have evolved. For mild asthma (Steps 1 and 2), the preferred approach (Track 1) is to use an as-needed low-dose ICS/formoterol combination for both reliever and controller therapy. This ensures that the patient receives an anti-inflammatory ICS whenever they experience symptoms. Daily low-dose ICS plus as-needed SABA is the alternative approach (Track 2). As-needed SABA alone is no longer recommended for persistent asthma due to risks associated with SABA overuse without an ICS. LTRAs are less effective alternatives.

Start this quiz